Three Seasons Wealth LLC Has $585,000 Position in Exelixis, Inc. $EXEL

Three Seasons Wealth LLC lessened its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 52.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,357 shares of the biotechnology company’s stock after selling 14,919 shares during the quarter. Three Seasons Wealth LLC’s holdings in Exelixis were worth $585,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its stake in shares of Exelixis by 692.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 140,446 shares of the biotechnology company’s stock worth $6,156,000 after purchasing an additional 122,720 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Exelixis by 18.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,383,820 shares of the biotechnology company’s stock valued at $60,307,000 after purchasing an additional 216,048 shares during the last quarter. Northwest Wealth Management LLC bought a new stake in Exelixis in the fourth quarter worth $253,000. Spire Wealth Management increased its position in Exelixis by 4.5% during the fourth quarter. Spire Wealth Management now owns 9,643 shares of the biotechnology company’s stock worth $423,000 after buying an additional 416 shares during the last quarter. Finally, Kaufman Rossin Wealth LLC increased its position in Exelixis by 18.7% during the fourth quarter. Kaufman Rossin Wealth LLC now owns 6,360 shares of the biotechnology company’s stock worth $279,000 after buying an additional 1,000 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Exelixis Stock Up 2.2%

Shares of EXEL opened at $42.89 on Wednesday. The stock’s 50-day moving average price is $42.72 and its 200 day moving average price is $42.04. The firm has a market capitalization of $11.14 billion, a price-to-earnings ratio of 15.48, a P/E/G ratio of 0.94 and a beta of 0.41. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. The company had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The company’s quarterly revenue was up 5.6% on a year-over-year basis. During the same quarter last year, the company earned $0.55 EPS. Equities research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EXEL. Morgan Stanley boosted their price target on Exelixis from $48.00 to $49.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Barclays increased their price objective on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. UBS Group set a $41.00 price objective on Exelixis in a research note on Monday, January 5th. Bank of America cut Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 target price for the company. in a research report on Monday, January 5th. Finally, Wells Fargo & Company increased their price target on Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a report on Wednesday, February 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Exelixis has an average rating of “Hold” and a consensus price target of $46.94.

Insider Transactions at Exelixis

In other Exelixis news, Director Bob Oliver sold 30,250 shares of Exelixis stock in a transaction on Friday, February 13th. The shares were sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the sale, the director owned 21,120 shares in the company, valued at $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jack L. Wyszomierski sold 99,574 shares of the stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the completion of the transaction, the director owned 279,942 shares of the company’s stock, valued at approximately $12,320,247.42. This represents a 26.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 362,849 shares of company stock valued at $15,917,463 over the last 90 days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.